1Zoulim F, Darmaoui E and Trepo C. Inhibitory effect of penciclovir on the priming of hepadnavirus revers transcription. Abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy. Washington,DC: American Society Microbiology, 1995:182
2Shaw T and Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantionmers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology, 1996, 24(5) :996-1002
3Gill KS and Wood MJ. The clinical pharmacokinetics of famciclovir. Clin phamacokinet, 1996,31(1): 1 - 8
4Crumpacker C. The pharmacological profile of famciclovir. Semim Dematol,1996,15(2 Suppl 1 ): 14 - 26
5Stott GA.Famciclovir:a new systemic antiviral agent for herpesvirus infections. Am Fam Physician, 1997,55(7) :2501 - 4
6Christian Trepo. AASLD conference in Chicago Nov,ii,1996
7Main J, Brown JL, Howells C, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepatol, 1996,3(4):211- 5
8Singh N, Gayowski T, Wannstedt CF, et al. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation.Transplantation, 1997,63(10): 1415 - 9
9Klein M, Geoghegan J and Schmidt K. Conversion of recurrent delta-positive hepatitis B infection to seronegativity with famciclovir after liver transplantation. Transplantation, 1997,64( 1 ): 162 - 3
10Lau GKK,Liang R,Wu PC,et al. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogenic bone marrow transplantation. J hepatol, 1998,28(2) :359 - 368
1Chutima Pramoolsinsup . Management of viral hepatitis B. J Gastroenterol Hepatol, 2002, 2(17 ): 152- 162.
2Lau G K K , Tsiang M, Hou J , et al. Combinatinon therapy with lamwudine and famciclovir for chronic hepatitis B - infected Chirese patients: a viral dynamics study. Hepatology , 1999,32(2): 394 - 399.
3Schalm S W, Heathcote J , Cianciara J , et al. Lamivcldine and alpha interferon combination treatmeat of patients with chronic hepatitis B infection: a randonised trail. Gut ,2000,46(4) :562 - 568.
4Chaisomchit S, Tyrrell DL, Chang L J , et al . Development of replicative and nonreplicative hepatitis B virus vectors . Gene Ther , 1997,4(12): 1330 - 1340.
5Iu Putlitz J , Wieland S, Blum H E , et al . Antisense RNA Complementary to hepatitis B virus specifically inhibits viral replication . Gastroentrology, 1998,115(3) :702 - 713.
6Nako K , Nakata K , yamashita M , et al . ISGF - 3gmma is imolved in interferon - alpha induced suppressson of hepatitis B virus enhanceactivity J Biol chem, 1999,274(28) :28075 - 28078.
7Kweon yo , Goodman Z , DsenstagJL, etal . Decreasingfibrogenesis an immuno histochemical study of paired liver biopsies following lamivucline therapy for chronic hepatitis B. J Hepato , 2001,35:749.
8Lai el ,Ching CK, Twng A K , et al. lamivucline is effective in surppressing HBV- DNA in Chinese hepatis B swrfoue antigen carriers: a place controlled trial. Heptology , 1997,25 ( 1 ) :241 - 244.
9Villeneuve JP, condreay LD, willems B, et al. Lamivudine treatment for decompensated cirrhosis vesulting from chronic Hepatitis B. Heptology,2000, 31(1):207,210.
